dc.description.abstract |
Diseases produced by protozoan parasites are one of the main
cause of morbidity and mortality around the world, affecting millions of people.
Leishmaniasis is a disease complex caused by the species of haemoflagellate
protozoan parasites belonging to the genus Leishmania. This disease ranges
in severity from skin lesions to serious disfigurement and fatal systemic
infection. WHO has classified the disease as emerging and uncontrolled and
estimates that the infection results in 2 million new cases a year. There are 12
million people currently infected worldwide, and disease threatens 350 million
people in 88 countries. Current treatment is based on chemotherapy, which
relies on hand full of drug with serious limitations such as high cost, toxicity,
difficult route of administration and lack of efficacy in endemic areas. Till date
no vaccine is available.
There are two major forms of this disease are reported, visceral
leishmaniasis (VL) and cutaneous leishmaniasis (CL) as well as various other
cutaneous manifestations include mucocutaneous leishmaniasis (MCL),
diffuse cutaneous leishmaniasis (DCL) and Post kala-azar dermal
leishmaniasis (PKDL).
Visceral Leishmaniasis (VL) is a serious health problem in
eastern part of India i.e. almost all districts of Bihar, four districts of
Jharkhand, five districts of Uttar Pradesh and ten districts of West Bengal.
Standard drugs against VL are being compromised. Therefore there is urgent
need to develop new line of drug and drug targets. The pentavalent
antimonials such as meglumine antimoniate and sodium stibogluconate have
been recommended for the treatment of leishmaniasis for over 70 years. The
emergence of drug resistance against these drugs has detoriated the situation
and there is no prevention measures are available till date. Miltefosine is the
first recognized oral treatment for leishmaniasis, but resistance to miltefosine
has also been observed. Unfortunately very little information is available on
biochemical and molecular mechanism of emergence of resistance against
standard drugs. Therefore there is urgent need to develop a new class of drug
against leishmaniasis. The unusual localization of glycolytic enzymes in glycosomes of
kinetoplastida supposedly endows them with specific structural features, and
the crucial importance of glycolysis for the parasites energy supply makes the
glycosome and its constituting proteins ideal targets for specific drugs against
leishmaniasis. In the present thesis the triosephosphate isomerase (TIM)
enzyme of glycolytic pathway has been studied. Triosephosphate isomerase
is an enzyme of glycolytic pathway which interconverts glyceraldehyde 3-
phosphate to dihydroxyacetone phosphate. Till date there have been no
reports of cloning, overexpression and characterization of TIM from
Leishmania donovani. Keeping in view the importance of triosephosphate
isomerase for trypanosomatids, efforts have been made to characterize TIM
from L. donovani.
The complete ORF of 753 bp TIM gene was PCR amplified
from the L. donovani (Dd8) genomic DNA and cloned in pGEMT easy cloning
vector. Recombinant clone was sequenced in both direction using T7 forward
and SP6 reverse primers to confirm the sequence of amplicon. The nucleotide
sequence of LdTIM has been deposited in GenBank under Accession No.
DQ649411. The DNA sequence for coding region was found enriched in G+C
residues (61.9%) in comparison with A+ T residues (38.1%). Sequence
analysis showed that the amino acid of L. donovani TIM was highly
homologous to L. major TIM with 93 % identity. It exhibited 92 % and 88.10 %
identity with L.infantum and L.mexicana respectively. The signature sequence
AYEPVWAIGTG (166-176) as well as residues involved in catalytic
mechanism i.e lysine 13, asparagine 12, glutamic acid 168 and histidine 96
were found conserved. Potent differences were observed in LdTIM amino acid
sequence as compared with HTIM. The LdTIM has cysteine residue at
position 15 and glutamate at position 66 while the corresponding residues in
HTIM are methionine and glutamine respectively. These may be targeted to
find agents that selectively inhibit the parasite enzyme.
Leishmania proteins are generally insoluble in nature and tend
to form aggregate and appears as an inclusion bodies upon expression in
prokaryotic hosts. In practice, it is worthwhile to test several different
vector/host combinations to obtain the best possible yield of protein in its
functional form. The LdTIM ORF was subcloned in pET-28(a) expression vector and conditions were optimized for the high expression of active LdTIM
in E. coli. The protein was purified using Ni-NTA and traditional methods using
gel filtration followed by ion exchange chromatography. Approximately 7 μg
purified LdTIM was obtained by Ni-NTA chromatography with specific activity
of 5090 units/mg. Further, several attempts were made to increase the
amount of protein but the desired protein failed to bind with the Ni-NTA
column, suggesting that the His-tag was not free for the matrix. It may be
possible that protein was buried inside during the folding process hence the
classical method of gel filtration (Sephadex G- 100) and ion exchange
chromatography (Q- Sepharose) was followed. The recombinant LdTIM has
27.6 kDa in size, dimeric in nature and found functional. The specific activity
of purified LdTIM was 8.7 x 103 μm/min/mg. The yield of recombinant LdTIM
was ~ 17.5 mg/L of E. coli culture. Biochemical studies revealed that the Km
and Vmax for the substrate glyceraldehyde 3- phopshate were 328 μM and
2011 μM/ min. The optimum pH of LdTIM is ranging from pH 7.2-9.0 and
temperature of 25 °C. LdTIM was found sensitive towards urea and GdmCl as
manifested by loss of enzyme activity. The protein looses 75 % and 85 %
activity at the concentration of 2 M solution of urea and GdmCl respectively
and the complete loss of enzyme activity was observed at 3 M concentration
of urea and GdmCl. The effect of increasing concentrations of SDS on the
enzymatic activity of LdTIM showed that the enzyme looses 6.26 % and 83.89
% activity at concentration of 0.3 mM and 0.45 mM respectively. However, at
concentration of 0.60 mM, a complete loss of enzyme activity was observed.
In order to achieve specific inhibition of LdTIM a cysteinereactive
agent methylmethane thiosulphonate (MMTS) was used as probe, in
order to test its effect on enzyme activity and structure. The MMTS inhibited
75% LdTIM enzyme activity within 15 minutes at 250 μM MMTS
concentration. Higher concentrations of MMTS or longer preincubation time
did not increase the extent of inhibition. LdTIM was found more sensitive to
MMTS than reported for LmTIM and TbTIM. MMTS inhibited 80% of LmTIM
and 90% of TbTIM activity at concentration of 1000μM and 400μM
respectively. In TcTIM 100 % inactivation was achieved with in 15 minutes at
15 μM concentration. These results illustrates that LdTIM exhibit differences
to MMTS with markedly similar proteins with identical or similar cysteine contents. The Km of LdTIM treated with 1mM MMTS and 3 mM MMTS
concentration was 0.34 mM which were slightly different with respect to
untreated LdTIM which has Km of 0.328 mM suggesting MMTS didn’t affect
the rate of reaction.
The urea induced structural changes in LdTIM was monitored
by intrinsic fluorescence. The fluorescence spectra LdTIM at 0 M urea
concentration showed a peak at 338 nm indicating that tryptophan molecule(s)
are not completely buried in the native protein but partially exposed to the
solvent. As the concentration of urea increases from 0 M to 8 M, a shift in
wavelength from 338 nm to 354.3 nm were recorded with decrease in
fluorescence which shows that urea induces the exposure of the buried
tryptophan residues.
The chromatogram of native LdTIM showed a single elution
peak at 9.75 ml which corresponds to the molecular weight of ~54 kDa while
SDS-PAGE analysis showed only a single band of 27.6 kDa, suggesting that
the LdTIM is a homodimer. The LdTIM samples incubated with MMTS
exhibited a second peak appearing at larger elution volume i.e 12.5 ml
suggesting that MMTS dissociates the LdTIM dimer inducing the formation of
a monomer.
The dye ANS has been used as a probe for the detection of
non-polar surface patches and “molten globule” intermediates. The
fluorescence emission spectrum of ANS was not perturbed in the
presence of LdTIM, suggesting that ANS did not bind significantly to the
native protein with maximum of the emission curve at 490 nm. On the
other hand, increase in ANS fluorescence with shift in wavelength to 500
nm was observed in LdTIM incubated with MMTS as compared to native
LdTIM. This indicates that MMTS induces the exposure of buried hydrophobic
surfaces and /or cationic groups in LdTIM.
Further the effect of bovine serum albumin on the reactivation of
LdTIM was investigated. The recombinant LdTIM expressed into pET-23a (+)
expression vector was appeared as inclusion bodies. The available protein in
inclusion bodies was solubilized in 6M guanidine hydrochloride and purified
using Ni-NTA affinity chromatography. Denatured purified LdTIM was allowed
to reactivate at protein concentrations, ranging from 1 to 20μg/ml in the presence and absence of 10 μg/ml BSA in the reactivation media. The
maximum reactivation of denatured protein, i.e., 3455 μM/min/mg was
observed at 5 h with 10 μg/ml LdTIM concentration with BSA in reactivation
buffer. The titration curve of different concentrations of BSA (0 - 80 μg/ml) on
reactivation of LdTIM at 10 μg/ml showed the maximal effect of BSA was
attained at concentration of 10 μg/ml in 5 h. The fluorescence emission
spectrum of ANS for LdTIM at 5 h showed maximum of the emission curve at
510 nm while maximum of the emission curve was shifted toward shorter
wavelength i.e. 490 nm with increase in fluorescence in LdTIM samples
incubated for 5 hours in presence of 10 μg/ml BSA, suggesting that BSA
induces the structural changes in denatured LdTIM. Here we conclude that
the BSA assists in the refolding and regain of LdTIM enzyme activity by
providing framework for structure formation
The energy minimized and refined 3D structure of the LdTIM
was built by using homology modeling based on the known crystal structure of
TIM from L. mexicana as a template. The RMSD difference between the
template and target is found to be 0.128 Å only. The modeled LdTIM was
validated by PROCHECK, ProSA II and WHATIF. The results showed that the
backbone conformation (PROCHECK), the residue interaction (Prosa II) and,
the residue contact (WHATIF) are well within the limits established for the
reliable structures and these tests suggest that we have obtained a good
model for LdTIM to further characterize its binding site and explore its
interactions with the substrate. All the residues around the active site of TIM
protein in L. mexicana are found to be conserved in LdTIM. Most of the non
conserved residues belong to surface region of the protein. Secondary
structure elements consist of 11 alpha helices and 8 beta sheets with
intermittent loop regions
This is the first report of purification and characterization of
recombinant TIM from Leishmania donovani. Studies on recombinant LdTIM
will help in evaluating this enzyme as potential drug target for visceral
leishmaniasis. |
en |